Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-12-16
2000-09-12
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 314436, A61K 314439
Patent
active
06117890&
DESCRIPTION:
BRIEF SUMMARY
This invention provides a method for treating or alleviating the symptoms of bipolar disorder, comprising administering an effective amount of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (hereinafter referred to as "xanomeline").
Bipolar Disorder is a psychiatric condition which is prevelant across cultures and age groups. The lifetime prevalence of Bipolar Disorder can be as high as 1.6%. DSM-IV, p. 353 (American Psychiatric Association, Washington, D.C. 1994). Bipolar Disorder is a recurrent disorder characterized by one or more Manic Episodes immediately before or after a Major Depressive Episode or may be characterized by one or more Major Depressive Episodes accompanied by at least one Hypomanic Episode. Additionally, the symptoms must cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. In some cases the Hypomanic Episodes themselves do not cause impairment; however, the impairment may result from the Major Depressive Episodes or from a chronic pattern of unpredictable mood episodes and fluctuating unreliable interpersonal and occupational functioning. The symptoms of Bipolar Disorder must not be better accounted for by a psychotic condition or due to the direct physiological effects of a medication, other somatic treatments for depression, drugs of abuse, or toxin exposure.
Bipolar Disorder is associated with a significant risk of completed suicide. Further, the patient suffering from Bipolar Disorder is likely to suffer from school truancy, school failure, occupational failure, or divorce.
Therefore, Bipolar Disorder is a serious, fairly prevelant, psychological condition which is clearly distinguished from psychotic conditions such as schizophrenia. DSM-IV, p. 353 (American Psychiatric Association, Washington, D.C. 1994). DSM-IV, p. 353 (American Psychiatric Association, Washington, D.C. 1994).
Applicants have discovered that xanomeline, thought to be a muscarinic agonist, can be useful for treating Bipolar Disorder. The present invention relates to a method of treating Bipolar Disorder. More specifically, the invention provides a method of treating Bipolar Disorder in humans using xanomeline.
As noted hereinbefore, the compound employed in the method of the present invention is known. Methods of preparing the compound, as well as pharmaceutical formulations containing the compound, are taught by Sauerberg in U.S. Pat. No. 5,043,345 (hereinafter refered to as the "'345 patent") herein incorporated by reference. The '345 patent teaches that xanomeline can be useful for treating Alzheimer's Disease and as stimulants of the cognitive function of the forebrain and hippocampus of mammals. Applicants have discovered that xanomeline can be useful for the treatment of bipolar disorder. Xanomeline may address the long felt need for treatments having an acceptable safety profile and provide effective relief to the patient suffering from bipolar disorder.
The present invention provides a method for treating bipolar disorder in humans comprising administering to a human in need thereof, an effective amount of a compound of Formula I: ##STR1## or a pharmaceutically acceptable salt or solvate thereof.
The term "effective amount", as used herein, represents an amount of compound necessary to prevent or treat a human susceptible to or suffering from Bipolar Disorder following administration to such human. The active compound is effective over a wide dosage range. For example, dosages per day will normally fall within the range of about 0.005 to about 500 mg/kg of body weight. In the treatment of adult humans, the range of about 0.05 to about 100 mg/kg, in single or divided doses, is preferred. However, it will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances including the condition to be treated, the choice of compound to be administered, the age, weight, and response of the individual patient, the severity of the patient's s
REFERENCES:
patent: 5041455 (1991-08-01), Sauerberg et al.
patent: 5043345 (1991-08-01), Sauerberg et al.
patent: 5328923 (1994-07-01), Sauerberg et al.
patent: 5328924 (1994-07-01), Sauerberg et al.
patent: 5488056 (1996-01-01), Bodick et al.
patent: 5708014 (1998-01-01), Bodick et al.
Rapaport, et al., Biol. Psychiatry, 29, 658-664 (1991).
Katzung, B.G., Basic & Clinical Pharmacology, (Appleton & Lange, Norwald), 90-94 (1995).
Sauerberg, et al., J. Med. Chem., 35, 2274-2283 (1992).
Bymaster Franklin P
Shannon Harlan E
Eli Lilly and Company
Spivack Phyllis G.
Stemerick David M.
Vorndran-Jones MaCharri
LandOfFree
Method for treating bipolar disorder does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating bipolar disorder, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating bipolar disorder will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-96573